Based on a recent study from our group, in which we showed that low dose locally delivered VitD/Dexa was effective at halting the progress of atherosclerosis, via induction of IL-10-producing regulatory leukocytes instead of prompting direct systemic effects (30), here we hypothesized that other immunoregulatory small molecules administered on a similar sc REMID strategy should also be able to restore the pro/anti-inflammatory balance and impact disease. Here, IL10 is linked to atherosclerosis.